- Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
-
Hisamatsu , Kunisaki R, Nakamura S, Tsujikawa , Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M, CERISIER Trial group
- KMID: 2417663
- Intest Res.
- 2018 Jul;16(3):494-498.
- doi: 10.5217/ir.2018.16.3.494
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
-
Motohashi T, Yabuno A, Michimae H, Ohishi T, Nonaka M, Takano M, Nishio S, Fujiwara H, Keiichi K, Kondo E, Sugiyama T, Tabata T
- KMID: 2526299
- J Gynecol Oncol.
- 2021 Jan;32(1):e9.
- doi: 10.3802/jgo.2021.32.e9
Objective: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m2 every 4 weeks. While 40 mg/m2 has recently been used in clinical practice, evidence supporting this use remains... -
- CITED
-
- Close
- SHARE
-
- Close
